Yes, many neurofibromatosis tumors can be removed, but whether yours can depends on its type, its location, and how tightly it wraps around nerves. A single dermal neurofibroma lifts out in a 20-minute office procedure under local anesthetic. A large plexiform tumor threaded through a major nerve may be only partly removable, or not removable at all without permanent weakness. Surgeons therefore weigh tumor type, growth rate, and nerve sacrifice against observation, debulking, or a MEK inhibitor such as selumetinib. Roughly two-thirds of inoperable pediatric plexiform tumors shrink at least 20 percent on that drug.
Why the Tumor Type Decides Whether Removal Is Possible
Neurofibromatosis is an umbrella term for three distinct genetic conditions, and each produces tumors with a different surgical personality. NF1, the most common, affects roughly 1 in 3,000 births, per CDC estimates. NF2-related schwannomatosis runs at about 1 in 25,000 to 1 in 33,000. Non-NF2 schwannomatosis is rarer, with estimates near 1 in 40,000.
The 2022 international consensus renamed NF2 as NF2-related schwannomatosis and split the remaining cases by driving gene, LZTR1 or SMARCB1 (Plotkin et al., 2022). The relabeling matters clinically because each label predicts which tumors appear and where. Vestibular schwannomas are bilateral in roughly 95 percent of NF2-related cases. Multiple painful schwannomas without vestibular tumors point toward a different diagnosis.
Underneath the labels sits one shared mechanism. A Schwann cell loses both working copies of a growth brake. In NF1 the brake is neurofibromin, which switches off RAS; in NF2 it is merlin, which restrains several growth pathways. With the brake gone, RAS/MAPK signaling stays on and the cell divides when it should not.
That mechanism explains the shape of the tumor. A dermal neurofibroma grows in the skin's collagen, pushes surrounding tissue aside, and develops a thin pseudocapsule. A surgeon can find that plane and follow it. A plexiform neurofibroma grows inside nerve fascicles and expands them, so tumor and nerve occupy the same physical space.
In plain terms: a skin neurofibroma is a grape sitting in pudding, while a plexiform neurofibroma is a knot grown through the strands of a net.
This is why the question of whether a neurofibromatosis tumor can be removed is never a single yes or no. It is a statement about one lesion, at one site, in one patient. Roughly 95 percent of adults with NF1 have dermal neurofibromas, often in the hundreds, and 20 to 50 percent have at least one plexiform tumor.
How Often Can Neurofibromatosis Tumors Be Removed?
Removal rates depend entirely on which tumor you count. Dermal neurofibromas are almost always removable, and most come out under local anesthetic in 15 to 30 minutes. Plexiform neurofibromas are a different statistic. Published surgical series report gross total resection in roughly 30 to 50 percent of plexiform tumors that reach the operating room.
The phrase "that reach the operating room" carries the weight. Many plexiform tumors are never offered to a surgeon, because imaging shows involvement of the brachial or sacral plexus, the airway, or the orbit. Others are asymptomatic and stable, and the risk of operating exceeds the risk of watching.
Size changes the arithmetic. A plexiform tumor under 3 cm in a limb often has a dissectable plane; one over 10 cm crossing a joint usually does not. Growth rate matters as much as size. Trial criteria used since 2016 define progression as a 20 percent increase in tumor volume, and a lesion gaining that much per year is a candidate for intervention.
Vestibular schwannomas in NF2 follow a third pattern. Roughly 30 to 50 percent grow within three to five years of diagnosis, while the rest stay stable for years. Surgery is reserved for tumors that grow, compress the brainstem, or cause progressive hearing loss.
Surgical Options by Tumor Type
Dermal neurofibroma removal is the simplest operation in this field. After local lidocaine with epinephrine, the surgeon makes an ellipse around the lesion, lifts it off the underlying fat, and closes with two to four sutures. The procedure takes 15 to 30 minutes, the scar is usually 1 to 2 cm, and patients return to normal activity the same day. Per-lesion cost in the United States typically runs USD 150 to USD 400.
Plexiform debulking is major surgery. Expect general anesthesia, motor and sensory nerve monitoring, and often a cavitational ultrasonic aspirator to liquefy vascular tissue. Operations last 3 to 8 hours, hospital stays run 2 to 5 days, and blood loss can exceed 1 to 2 liters in large pelvic or limb tumors. The goal is usually partial: remove 50 to 80 percent of the volume to relieve pain or pressure while preserving nerve function.
Spinal neurofibromas are removed through laminectomy or a minimally invasive corridor, with neuromonitoring throughout. Roughly 40 percent of adults with NF1 have spinal tumors visible on MRI, but most remain silent for years. Surgery is triggered by pain, weakness, bowel or bladder change, or documented growth.
Vestibular schwannoma surgery uses three corridors: retrosigmoid, translabyrinthine, and middle fossa. For tumors under 1.5 cm, specialized centers report hearing preservation in 50 to 70 percent of cases and facial nerve preservation above 95 percent. For tumors over 3 cm, facial nerve preservation falls to roughly 70 to 85 percent.
Malignant peripheral nerve sheath tumors are handled differently from every benign lesion above. They require wide local excision with negative margins, usually followed by radiation. Five-year survival sits near 50 to 60 percent, and local recurrence occurs in 20 to 30 percent even with adequate margins.
Risks and Complication Rates
Blood loss is the defining risk of plexiform surgery, because these tumors contain thin-walled vessels and lack normal vasoconstriction. Surgeons cross-match blood beforehand and sometimes use tranexamic acid or cell salvage. A single large pelvic resection can require transfusion of 2 to 4 units.
Nerve injury is the deliberate trade-off. Resecting tumor that infiltrates a fascicle means sacrificing the fibers inside it, which produces numbness in a defined patch or weakness in a specific muscle group. Damage to a major plexus can leave permanent deficits, which is why subtotal removal is often the safer target.
Cerebrospinal fluid leak complicates roughly 8 to 10 percent of vestibular schwannoma operations and usually resolves with bed rest or a lumbar drain. Wound infection after neurofibroma excision runs about 2 to 5 percent, higher in large resections with drains. Permanent facial weakness affects under 5 percent of small-tumor cases but 15 to 30 percent of very large ones.
Anesthesia carries a specific caveat that patients should raise themselves. Airway neurofibromas, cervical spine instability, and restrictive lung disease from severe scoliosis can all complicate intubation. A preoperative anesthesia consult with imaging review is reasonable before any general anesthetic.
MEK inhibitors have their own risk profile, distinct from surgery. Diarrhea, acneiform rash, paronychia, and elevated creatine kinase are common. Cardiac ejection fraction can decline, so echocardiograms are repeated every 3 to 6 months while treatment continues.
Recurrence Rates and What Drives Them
The best predictor of recurrence is the margin achieved at the first operation. After gross total resection, roughly 10 to 20 percent of plexiform tumors regrow within five years. After subtotal debulking, 40 to 60 percent regrow in the same window, and many patients face a second operation within a decade.
Age at surgery is the second predictor. Tumors removed during active growth phases, particularly in children under 10, regrow more often than the same tumor removed after growth stabilizes. Hormonal shifts at puberty and pregnancy can also reactivate quiescent lesions.
A dermal neurofibroma recurs in under 5 percent of individual excisions, but the skin keeps producing new ones. Patients who have 40 lesions removed often count a similar number again within a few years. That is new tumor formation, not surgical failure, and it is worth saying out loud before the first operation.
In plain terms: removing a neurofibroma eliminates that tumor, not the tendency to make tumors.
Malignant transformation is the outcome that reshapes every risk discussion. Registry estimates put the lifetime risk of malignant peripheral nerve sheath tumor at roughly 8 to 13 percent in NF1, with transformation of a preexisting plexiform tumor accounting for most cases. Those two figures are consistent, not contradictory: the 8 to 13 percent number describes the whole NF1 population, while the 5 to 10 percent figure describes a single plexiform tumor, so the population risk is largely built from the per-tumor risk. Growth acceleration, new persistent pain, and new hardness are the clinical signals.
The 20 percent yardstick cuts both ways and is worth reconciling. A tumor must shrink at least 20 percent in volume to count as a drug response, and must grow 20 percent to count as progression, which corresponds to only about a 6 percent change in diameter. A scan that looks "about the same" to the eye can cross either threshold.
| Approach | Best suited to | Typical volume effect | Durability | Main trade-off |
|---|---|---|---|---|
| Observation with MRI every 6 to 12 months | Stable, asymptomatic plexiform tumors under 3 cm | None; growth is common in childhood, slower in adults | Avoids all procedural risk | Growth can be missed between scans |
| Surgery, gross total resection | Well-defined tumors with a dissectable plane | 90 to 100 percent removal | 80 to 90 percent without regrowth at 5 years | Nerve sacrifice; 10 to 20 percent recurrence |
| Surgery, subtotal debulking | Large, painful, nerve-encased tumors | 50 to 80 percent removal | 40 to 60 percent regrow by 5 years | Repeat operations; blood loss |
| MEK inhibitor (selumetinib, mirdametinib) | Inoperable, symptomatic plexiform tumors | At least 20 percent shrinkage in 41 to 66 percent of patients | Regrowth typically begins within months of stopping | Daily dosing; GI, skin, and cardiac monitoring |
The selumetinib response figure comes from the 2016 SPRINT trial, which reported partial responses in about two-thirds of children with inoperable plexiform neurofibromas. The FDA approved the drug for that use in April 2020. Mirdametinib, approved in February 2025 for the same indication, produced responses in 41 percent of adults and 52 percent of children in its pivotal trial.
Recovery Timeline After Removal
| Time after surgery | What is happening | Typical milestones |
|---|---|---|
| Day 0 | Anesthesia recovery, drain in place for large resections | Pain controlled with oral or IV medication; first wound check |
| Days 1 to 3 | Swelling peaks; drain output monitored | Walking by day 1 to 2; drain removed at under 30 mL per day |
| Days 4 to 14 | Sutures or staples still in place | Wound review at 7 to 10 days; return to desk work for skin excisions |
| Weeks 3 to 6 | Soft tissue healing; numbness patterns declare themselves | Scar massage begins at 3 weeks; PT for limb weakness |
| Month 3 | First postoperative baseline MRI for plexiform or spinal tumors | Comparison scan becomes the reference for all future imaging |
| Months 6 to 12 | Scar matures; function plateaus | Return to full activity by 3 to 6 months after major debulking |
| Years 2 to 5 | Surveillance continues | Annual or biannual MRI; regrowth detected in the 10 to 60 percent who recur |
Timelines stretch in both directions. A single skin excision is a one-visit event with no imaging follow-up. A pelvic plexiform debulking can keep a patient off work for 8 to 12 weeks and may need compression garments for a year.
Red Flags and What to Do Next
Any of the following warrants an urgent call to an NF specialist rather than a routine appointment:
- A known plexiform tumor that grows noticeably over weeks rather than months
- New, persistent, or nighttime pain in a tumor that was previously painless
- A tumor that becomes hard, fixed, or warm to the touch
- New limb weakness, numbness, or loss of bowel or bladder control with a spinal tumor
- Rapidly worsening hearing, facial droop, or balance problems in NF2-related disease
Outside those red flags, the practical steps are unglamorous and effective. Get baseline whole-body MRI at a center that reads NF scans routinely, because community radiologists often undercall plexiform burden. Photograph and measure visible lesions every 6 months so growth is documented rather than remembered. Ask directly whether an inoperable plexiform tumor meets criteria for a MEK inhibitor before accepting a debulking operation that will need repeating.
Sequence surgery deliberately. Removing 30 small dermal lesions in one session under general anesthesia is reasonable; removing one large plexiform tumor with a 6-week recovery is a different calculation. Ask what function sits in the nerve the tumor has invaded, and ask what the plan is if that function is lost.
Genetic counseling belongs in the first few visits, not the last. About half of NF1 cases arise from new mutations with no family history, and sibling risk changes the conversation entirely. Baseline cardiac and ophthalmologic screening is standard for children with NF1, since optic pathway gliomas affect roughly 15 to 20 percent.
What surgery cannot do deserves equal billing. It cannot remove the genetic driver, prevent new tumors, or reliably halt a field of plexiform disease. Every operation is a local solution to a systemic problem. That is precisely why the modern treatment sequence often places surgery and MEK inhibition side by side rather than in competition, and why the honest answer to whether neurofibromatosis tumors can be removed is yes, sometimes, with a plan.